Quantification of cancer driver mutations in human breast and lung DNA using targeted, error-corrected CarcSeq.

ABSTRACT: There is a need for scientifically-sound, practical approaches to improve carcinogenicity testing. Advances in DNA sequencing technology and knowledge of events underlying cancer development have created an opportunity for progress in this area. The long-term goal of this work is to develop variation in cancer driver mutation (CDM) levels as a metric of clonal expansion of cells carrying CDMs because these important early events could inform carcinogenicity testing. The first step toward this goal was to develop and validate an error-corrected next-generation sequencing method to analyze panels of hotspot cancer driver mutations (hCDMs). The "CarcSeq" method that was developed uses unique molecular identifier sequences to construct single-strand consensus sequences for error correction. Ca

SUBMITTER: Harris KL 

PROVIDER: S-EPMC7756507 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature